(es tra DYE ole)
Breast cancer, metastatic: Treatment of metastatic breast cancer (palliation) in appropriately selected males and postmenopausal females.
Osteoporosis, postmenopausal, prevention: Prevention of postmenopausal osteoporosis.
Limitations of use: For use only in patients at significant risk of postmenopausal osteoporosis; consider use of nonestrogen medications.
Prostate cancer, advanced: Treatment of androgen-dependent advanced prostatic cancer (palliation).
Secondary amenorrhea, hypoestrogenism: Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure.
Vasomotor symptoms associated with menopause: Treatment of moderate to severe vasomotor symptoms associated with menopause.
Vulvar and vaginal atrophy associated with menopause: Treatment of moderate to severe vulvar and vaginal atrophy associated with menopause.
Limitations of use: When used solely for the treatment of vulvar and vaginal atrophy, consider topical vaginal products.
Note: The International Society for the Study of Women’s Sexual Health and The North American Menopause Society have endorsed the term genitourinary syndrome of menopause (GSM) as new terminology for vulvovaginal atrophy. The term GSM encompasses all genital and urinary signs and symptoms associated with a loss of estrogen due to menopause (Portman 2014).
Sign up for a 10-day FREE Trial now and receive full access to all content.